These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 1441026)

  • 21. The fate of patients with locally advanced bladder cancer treated conservatively with neoadjuvant chemotherapy, extensive transurethral resection and radiotherapy: 10-year experience.
    Serretta V; Lo Greco G; Pavone C; Pavone-Macaluso M
    J Urol; 1998 Apr; 159(4):1187-91. PubMed ID: 9507829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Is down-staging of advanced bladder cancer by neoadjuvant chemotherapy possible?--MVEC protocol].
    Hoch V; Noll F; Schreiter F
    Urologe A; 1992 Jul; 31(4):243-6. PubMed ID: 1514212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
    Zietman AL; Shipley WU; Kaufman DS; Zehr EM; Heney NM; Althausen AF; McGovern FJ
    J Urol; 1998 Nov; 160(5):1673-7. PubMed ID: 9783929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Bladder preservation for locally advanced bladder cancer by transurethral resection, systemic chemotherapy and radiation].
    Honda M; Satoh M; Tujimoto Y; Takada T; Matsumiya K; Fujioka H
    Hinyokika Kiyo; 2006 May; 52(5):331-5. PubMed ID: 16758720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Is neoadjuvant chemotherapy valid in invasive cancer of the bladder?].
    Matveev BP; Figurin KM
    Urol Nefrol (Mosk); 1998; (6):42-5. PubMed ID: 10051828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
    Soga N; Arima K; Sugimura Y
    Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy.
    Inoue K; Slaton JW; Karashima T; Yoshikawa C; Shuin T; Sweeney P; Millikan R; Dinney CP
    Clin Cancer Res; 2000 Dec; 6(12):4866-73. PubMed ID: 11156246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined treatment approaches in regionally advanced bladder cancer.
    Walther PJ
    Urol Clin North Am; 1992 Nov; 19(4):761-74. PubMed ID: 1441030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic chemotherapy for muscle invasive bladder cancer.
    Ondrus D; Hornák M; Bárdos A; Ondrus B
    Neoplasma; 1994; 41(5):263-8. PubMed ID: 7854496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.
    Lehmann J; Franzaring L; Thüroff J; Wellek S; Stöckle M
    BJU Int; 2006 Jan; 97(1):42-7. PubMed ID: 16336326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers].
    Takenaka A; Gotoh A; Hara I; Gohji K; Ogawa T; Arakawa S; Matsumoto O; Kamidono S; Hamami G; Itani A
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1909-15. PubMed ID: 2393308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The role of M-VAC polychemotherapy in the treatment of advanced urothelial carcinoma of the bladder].
    Stöckle M; Meyenburg W; Wellek S; Voges G; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
    Ann Urol (Paris); 1993; 27(1):51-7. PubMed ID: 7682388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Postoperative adjuvant M-VAC chemotherapy for invasive bladder cancer].
    Yamashita S; Taniguchi K; Morimitsu H; Suzu H; Kanetake H; Saito Y; Yushita Y; Sakuragi T
    Hinyokika Kiyo; 1992 May; 38(5):519-24. PubMed ID: 1609658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Neoadjuvant chemotherapy (M-VAC) in invasive cancer of the bladder. Our experience].
    González Enguita C; Caro Cebrián C; Roncalés Badal A; Gil Sanz MJ; Martínez Bengoechea J; Rioja Sanz LA
    Arch Esp Urol; 1990; 43 Suppl 2():197-204. PubMed ID: 2096779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy for bladder cancer.
    Muñoz A; Barceló JR; López-Vivanco G
    N Engl J Med; 2003 Dec; 349(23):2272-3; author reply 2272-3. PubMed ID: 14657442
    [No Abstract]   [Full Text] [Related]  

  • 37. Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer.
    Bex A; Nieuwenhuijzen JA; Kerst M; Pos F; van Boven H; Meinhardt W; Horenblas S
    Urology; 2005 Feb; 65(2):295-9. PubMed ID: 15708041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.
    Birtle AJ; Huddart RA
    BJU Int; 2006 Jun; 97(6):1348; author reply 1348-50. PubMed ID: 16686740
    [No Abstract]   [Full Text] [Related]  

  • 39. Systemic chemotherapy in regionally advanced bladder cancer. Theoretical considerations and results.
    Scher HI
    Urol Clin North Am; 1992 Nov; 19(4):747-59. PubMed ID: 1441029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
    Viens P; Gravis G; Bladou F; Lechevallier E; Baume D; Camerlo J; Cowen D; Coulange C; Serment G; Resbeut M; Maraninchi D
    Eur Cytokine Netw; 1996 Sep; 7(3):395-9. PubMed ID: 8954183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.